Inter-Tumor Heterogeneity-Melanomas Respond Differently to GM-CSF-Mediated Activation
| Autor: | Tsipi Meshel, Orit Sagi-Assif, Shlomit Ben-Menachem, Isaac P. Witz, Sapir Malka, Metsada Pasmanik-Chor, Sivan Izraely, Adi Moshe, Dave S.B. Hoon |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Myeloid Skin Neoplasms medicine.medical_treatment Mice Nude Article Immune system In vivo Cell Line Tumor Interleukin-1alpha melanoma Medicine Animals Humans brain metastasis metastatic microenvironment lcsh:QH301-705.5 Mice Inbred BALB C Predictive marker business.industry Tumor Necrosis Factor-alpha Melanoma Transendothelial and Transepithelial Migration Brain Endothelial Cells Granulocyte-Macrophage Colony-Stimulating Factor GM-CSF General Medicine medicine.disease Colony-stimulating factor medicine.anatomical_structure lcsh:Biology (General) Cellular Microenvironment Solubility Astrocytes Cancer research business Adjuvant Brain metastasis |
| Zdroj: | Cells Volume 9 Issue 7 Cells, Vol 9, Iss 1683, p 1683 (2020) |
| ISSN: | 2073-4409 |
| Popis: | Granulocyte-monocyte colony stimulating factor (GM-CSF) is used as an adjuvant in various clinical and preclinical studies with contradictory results. These were attributed to opposing effects of GM-CSF on the immune or myeloid systems of the treated patients or to lack of optimal dosing regimens. The results of the present study point to inter-tumor heterogeneity as a possible mechanism accounting for the contrasting responses to GM-CSF incorporating therapies. Employing xenograft models of human melanomas in nude mice developed in our lab, we detected differential functional responses of melanomas from different patients to GM-CSF both in vitro as well as in vivo. Whereas cells of one melanoma acquired pro metastatic features following exposure to GM-CSF, cells from another melanoma either did not respond or became less malignant. We propose that inter-melanoma heterogeneity as manifested by differential responses of melanoma cells (and perhaps also of other tumor) to GM-CSF may be developed into a predictive marker providing a tool to segregate melanoma patients who will benefit from GM-CSF therapy from those who will not. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|